Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: A phase II study

Journal of Clinical Oncology

Volumn 18, Issue 12, 2000, Pages 2378-2384

  Smith, Ian E ^a   Johnston, Stephen R D ^a   O'Brien, Mary E R ^a   Hickish, Tamas F ^a   De Boer, Richard H ^a   Norton, Alison ^a   Cirkel, Deborah T ^a   Barton, Claire M ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYLURACIL; FLUOROURACIL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEMALE; GRANULOCYTOPENIA; HUMAN; INFECTION; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT INDICATION;

EID: 0034126765     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.12.2378     Document Type: Article

References (35)

1. Ensminger WD, Rosowsky A, Raso V, et al. A clinical pharmacologic evaluation of hepatic arterial infusion of 5-fluoro-2′-deoxyruridine and 5-fluorouracil. Cancer Res 38:3784-3792, 1978
2. Lokich J, Bothe A, Fine N, et al: Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 48:2565-2568, 1981
3. Huan S, Pazdur R, Singhakowinta A, et al: Low-dose continuous infusion 5-fluorouracil: Evaluation in advanced breast cancer. Cancer 63:419-422, 1989
4. Cameron DA, Gabra H, Leonard RCF: Continuous 5-fluorouracil in the treatment of breast cancer. Br J Cancer 70:120-124, 1994
5. Regazzoni S, Pesce G, Marini G, et al: Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer. Ann Oncol 7:807-813, 1996
6. Cohen JL, Irwin LE, Marshall GH, et al: Clinical pharmacology of oral and intravenous 5-fluourouracil (NSC-19893). Cancer Chemother Rep 58:723-731, 1974
7. Abernethy DR, Alper JC, Wiemann MC, et al: Oral 5-fluourouracil in psoriasis: Pharmacokinetic-pharmacodynamic relationships. Pharmacol 39:78-88, 1989
8. Diasio RB, Harris BE: Clinical pharmacology of 5-fluourouracil. Clin Pharmacokinet 16:215-237, 1989
9. Spector T, Harrington JA, Porter DJ: 5-ethynyluracil (776C85): Inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 46:2243-2248, 1993
10. Lu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implications in 5-fluourouracil chemotherapy. Cancer Res 53:5433-5438, 1993
11. Baccanari DP, Davis ST, Knick VC, et al: 776C85: Effects on the pharmacokinetics and antitumor activity of 5-fluorouracil. Proc Natl Acad Sci USA 90:11064-11068, 1993
12. Schilsky RL, Hohneker J, Ratain MJ, et al: Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol 16:1450-1457, 1998
13. Baker SD, Khor SP, Adjei AA, et al: Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 14:3085-3096, 1996
14. Nightingale CE, Norman A, Cunningham D, et al: A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy. Eur J Cancer 33:398-403, 1997
15. Burris HA, Ravdin P, Gutheil J, et al: Eniluracil/5-FU in anthracycline and taxane refractory breast cancer. Proc Am Soc Clin Oncol 18:107a, 1999 (abstr 405)
16. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253, 1992
17. Gehan E: The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13:346-353, 1961
18. Ahmann DL, Bisel HF, Eagan RT, et al: Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer. Cancer Chemother Rep 58:877-882, 1974
19. Hoogstraten B, George SL, Samal B, et al: Combination chemotherapy and adriamycin in patients with advanced breast cancer. Cancer 38:13-20, 1976
20. Taylor SG, Gelber RD: Experience of the Eastern Cooperative Oncology Group with doxorubicin as a single agent in patients with previously untreated breast cancer. Cancer Treat Rep 66:1594-1595, 1982
21. Robert J: Epirubicin: Clinical pharmacology and dose-effect relationship. Drugs 45:20-30, 1993 (suppl 2)
22. Stuart-Harris RC, Bozek T, Pavlidis NA, et al: Mitoxantrone: An active new agent in the treatment of advanced breast cancer. Cancer Chemother Pharmacol 12:1-4, 1984
23. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Instit 83:1797-1805, 1991
24. Reichman BS, Seidman AD, Crown JPA, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
25. Nabholtz JM, Gelmon K, Bontenbal M, et al: Randomized trial of two doses of Taxol in metastatic breast cancer: an interim analysis. Proc Am Soc Clin Oncol 12:60, 1993 (abstr 42)
26. Slamon D, Leyland Jones B, Shak S, et al: Addition of Herceptin to first-line chemotherapy for HER-2 overexpressing metastatic breast cancer markedly increases anti-cancer activity: A randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 16:98a, 1998 (abstr 377)
27. Dieras V, Fumoleau P, Chevallier B, et al: Second EORTC-clinical screening group (CSG) phase II trial of taxotere (docetaxel) as first line chemotherapy (CT) in advanced breast cancer. Proc Am Soc Clin Oncol 13:78, 1994 (abstr 115)
28. Fumoleau P, Delgado FM, Delozier T, et al: Phase II trial of weekly intravenous vinorelbine in first-line metastatic breast cancer chemotherapy. J Clin Oncol 11:1245-1252, 1993
29. Romero A, Rabinovich MG, Vallejo CT, et al: Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 12:336-341, 1994
30. Vogel C, O'Rourke M, Winer E, et al: Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 10:397-402, 1999
31. Mani S, Beck T, Chevlen E, et al: A phase II open-label study to evaluate a 28-day regimen of oral 5-fluorouracil (5-FU) plus 776C85 for the treatment of patients with previously untreated metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 17:281a, 1998 (abstr 1083)
32. Goldberg RM, Kugler J, Sargent DJ, et al: A phase II trial of a seven day regimen of oral 776C85 plus a five-day regimen of oral 5-fluorouracil (5-FU) in untreated patients (pts) with metastatic colorectal cancer (M-CRC): A North Central Cancer Treatment Group Study. Proc Am Soc Clin Oncol 17:282a, 1998 (abstr 1084)
33. Pazdur R, Lassere Y, Rhodes V, et al: Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12:2269-2300, 1994
34. Blum J, Jones SE, Buzdar AU, et al: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485-493, 1999
35. O'Shaughnessy J, Moiseyenko V, Bell D, et al: A randomized phase II study of Xeloda (Capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged ≥ 55 years. Proc Am Soc Clin Oncol 17:103a, 1998 (abstr 398)